The broad utility of ctDNA could classify HCC subtypes such as MYC vs. CDK6 mutants as illustrated by Ikeda et al. in Table II, guiding personalised therapies for HCC patients. The gene discussed is CDK6; the disease is hepatocellular carcinoma.